Since NLRP3 inflammasome pathway activation contributes significantly to PD neuroinflammation, targeting NLRP3 as a PD therapeutic strategy is a promising approach that has been gaining increasing attention over the recent years. The gene discussed is NLRP3; the disease is Parkinson disease.